Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Slides:

Advertisements

Similar presentations

Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention.

Advertisements

From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis Ashok.

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Usefulness of Outpatient Bleeding Risk Index to Predict Bleeding Complications in Patients With Long-term Oral Anticoagulation Undergoing Coronary Stenting

Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data

Volume 70, Issue 1, Pages (July 2017)

Incidence and Outcomes of Asthma in the Elderly

Trends in Outcomes of Revascularization for Left Main Coronary Disease or Three- Vessel Disease With the Routine Incorporation of Fractional Flow Reserve.

Comparative Survival After Transapical, Direct Aortic, and Subclavian Transcatheter Aortic Valve Implantation (Data from the UK TAVI Registry) Georg.

Outcome of Noncardiac and Nonvascular Surgery in Patients With Mechanical Heart Valves Murat Biteker, MD, Ahmet İlker Tekkeşin, MD, Mehmet Mustafa Can,

An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian.

Impact of Co-morbidity on the Risk of First-Time Myocardial Infarction, Stroke, or Death After Single-Photon Emission Computed Tomography Myocardial Perfusion.

Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population Susan Colilla, PhD, MPH, Ann Crow, MLS,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Community-Based Mind–Body Meditative Tai Chi Program and Its Effects on Improvement of Blood Pressure, Weight, Renal Function, Serum Lipoprotein, and.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

American Heart Journal

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without.

Volume 55, Issue 3, Pages (May 2010)

Frontiers of anticoagulation therapy for atrial fibrillation

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Moderate Pulmonary Embolism Treated With Thrombolysis (from the “MOPETT” Trial) Mohsen Sharifi, MD, Curt Bay, PhD, Laura Skrocki, DO, Farnoosh Rahimi,

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the.

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Two-Year Clinical Outcomes After Enhanced External Counterpulsation (EECP) Therapy in Patients With Refractory Angina Pectoris and Left Ventricular Dysfunction.

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting Danny Chu, MD, Faisal.

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Epidemiology of Myelodysplastic Syndromes

Trend in Mortality after Stroke with Atrial Fibrillation

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update Mate Vamos, MD, PhD, Julia Wiebke Erath,

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Apurva O. Badheka, MD, Ankit Rathod, MD, Mohammad A

Prolonged QTc affects short-term and long-term outcomes in patients with normal left ventricular function undergoing cardiac surgery Nattachai Anantasit,

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Volume 7, Issue 4, Pages (April 2010)

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

James L. Cox, MD, Niv Ad, MD, Terry Palazzo, RN, MS

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement Thomas.

Volume 16, Issue 1, Pages 3-9 (January 2019)

The Reply The American Journal of Medicine

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

Joseph R. Schneider, MD, PhD, Julie S. Droste, BSN, RN, John F

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Long-term Effect of Chronic Oral Anticoagulation with Warfarin after Acute Myocardial Infarction Salman A. Haq, MD, John F. Heitner, MD, Terrence J.

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

Volume 10, Issue 9, Pages (September 2013)

A Post-cure Complication

The American Journal of Medicine

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Treatment versus Transplant for Challenging Hematologic Disorders

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Presentation transcript:

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation Victoria Jacobs, NP, Heidi T. May, PhD, Tami L. Bair, RN, Brian G. Crandall, MD, Michael J. Cutler, DO, PhD, John D. Day, MD, Charles Mallender, MD, Jeffrey S. Osborn, MD, Scott M. Stevens, MD, J. Peter Weiss, MD, Scott C. Woller, MD, T. Jared Bunch, MD American Journal of Cardiology Volume 118, Issue 2, Pages 210-214 (July 2016) DOI: 10.1016/j.amjcard.2016.04.039 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Survival curve free of new stroke or TIA in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Survival curve free of major bleeds in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Survival curve free of total mortality in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 4 Long-term incident dementia events in patients with AF compared by DOACs and warfarin treatment. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 5 Survival curve for composite outcome of dementia, stroke, and TIA among DOAC and warfarin groups. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions